Abstract |
Apolipoprotein C2 ( ApoC2) is a key activator of lipoprotein lipase for plasma triglyceride metabolism. ApoC2-deficient patients present with severe hypertriglyceridemia and recurrent acute pancreatitis, for whom the only effective treatment is the infusion of normal plasma containing ApoC2. However, since ApoC2 has a fast catabolic rate, a repeated infusion is required, which limits its clinical use. To explore a safe and efficient approach for ApoC2 deficiency, we herein established an adeno-associated virus expressing human ApoC2 (AAV-hApoC2) to evaluate the efficacy and safety of gene therapy in ApoC2-deficient hypertriglyceridemic hamsters. Administration of AAV-hApoC2 via jugular or orbital vein in adult and neonatal ApoC2-deficient hamsters, respectively, could prevent the neonatal death and effectively improve severe hypertriglyceridemia of ApoC2-deficient hamsters without side effects in a long-term manner. Our novel findings in the present study demonstrate that AAV-hApoC2-mediated gene therapy will be a promising therapeutic approach for clinical patients with severe hypertriglyceridemia caused by ApoC2 deficiency.
|
Authors | Chun Yang, Wenhong Tian, Sisi Ma, Mengmeng Guo, Xiao Lin, Fengying Gao, Xiaoyan Dong, Mingming Gao, Yuhui Wang, George Liu, Xunde Xian |
Journal | Molecular therapy. Methods & clinical development
(Mol Ther Methods Clin Dev)
Vol. 18
Pg. 692-701
(Sep 11 2020)
ISSN: 2329-0501 [Print] United States |
PMID | 32802915
(Publication Type: Journal Article)
|
Copyright | © 2020 The Author(s). |